Improving patient outcomes after lung cancer surgery using a mobile platform

Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform

This study is testing a mobile app to help lung cancer patients manage their recovery after surgery by tracking symptoms and improving communication with their doctors.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 216 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Shanghai Chest Hospital (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT06483295 on ClinicalTrials.gov

What this trial studies

This study aims to enhance the management of postoperative symptoms in lung cancer patients through a mobile internet platform integrated with WeChat. By focusing on patient-reported outcomes (PROs), the research seeks to monitor symptoms like pain and coughing more effectively, thereby improving patient engagement and follow-up care. The study will create a prospective database to analyze factors affecting recovery and assess the role of interactive platforms in enhancing patient care. The use of internet technology is expected to facilitate better communication between patients and healthcare providers post-surgery.

Who should consider this trial

Good fit: Ideal candidates are patients diagnosed with Stage I-III lung cancer who have undergone surgical resection and are familiar with using WeChat on their smartphones.

Not a fit: Patients who have received non-surgical anti-tumor therapies or have serious comorbidities that prevent them from undergoing surgery may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve the quality of life and recovery outcomes for lung cancer patients after surgery.

How similar studies have performed: While the use of mobile platforms for patient engagement is gaining traction, this specific approach focusing on lung cancer postoperative care is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
2. Owns and uses a smartphone and can use WeChat.
3. Volunteer to participate in this study and sign an informed consent form.

Exclusion Criteria:

1. Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period.
2. After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen.
3. After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge.
4. At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.

Where this trial is running

Shanghai, Shanghai Municipality

• Zuodong Song — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Principal investigator: Xinghua Cheng, MD — Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• Study coordinator: Xinghua Cheng, MD

Conditions Lung Cancer; patient-reported outcomes; Internet